Search
Results
centersUniversity of Sheffield
University of Milan Medical School
Vincenzo Silani
Nicola Ticozzi
Alberto Doretti
specialistsClaudia Morelli
pageRegister
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, a phase 3 trial investigating the drug TUDCA in individuals with ALS. Unfortunately, the results have showed that taking the drug did not slow down the disease progression.
Sarsha Wilson
newsAmylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. After analysis, the research drug AMX0035 unfortunately shows no effect in the treatment of ALS.
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for QALSODY (better known as Tofersen). If authorized by the European Commission (EC), QALSODY (Tofersen) will be approved in the European Union as a tr...
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE clinical trial. Unfortunately, analysis of data showed that the investigated drug edaravone was not effective.